Till debt do us part: will other startups go the PharmEasy way, and other top tech & startup stories this week
This weeks ETtech newsbreak on PharmEasy going for a rights issue at a price 90% lower than its peak valuation of $5.6 billion to repay debt has tripped alarm bells in several startups that have taken debt financing.